GlassScriptPhysician profile
Harry A Carter
NPI 1538165261
$3,057.93
in general payments reported to CMS, 2019-2025
31 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $300 · 2021: $736 · 2022: $338 · 2023: $774 · 2024: $333 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $321.16 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $280.25 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $237.64 | 2022-2023 | Austedo Xr, Austedo, Uzedy |
| Sanofi-Aventis U.S. LLC | $223.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $199.78 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $162.03 | 2021-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $160.01 | 2021-2025 | Ozempic, Rybelsus |
| Alkermes, INC. | $149.42 | 2022-2025 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.86 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.10 | 2020-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $110.58 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.64 | 2023 | |
| Mylan Specialty L.P. | $100.84 | 2020-2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $84.22 | 2020-2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $71.38 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $64.02 | 2019 | |
| Lundbeck LLC | $63.16 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $62.50 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $50.44 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $48.41 | 2024-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $43.76 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $36.11 | 2022-2023 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $31.91 | 2021-2022 | |
| Exact Sciences Corporation | $30.58 | 2025 | Cologuard Collection Kit |
| Insulet Corporation | $28.32 | 2023 | Omnipod |
| Abbvie INC. | $23.46 | 2021 | |
| Dexcom, INC. | $22.19 | 2023 | Dexcom G6 Transmitter |
| Itamar Medical INC | $17.40 | 2025 | Watchpatone |
| Tandem Diabetes Care, INC. | $14.59 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $13.18 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.